WO2003008380A1 - Carboxylic acid derivatives - Google Patents

Carboxylic acid derivatives Download PDF

Info

Publication number
WO2003008380A1
WO2003008380A1 PCT/JP2002/007250 JP0207250W WO03008380A1 WO 2003008380 A1 WO2003008380 A1 WO 2003008380A1 JP 0207250 W JP0207250 W JP 0207250W WO 03008380 A1 WO03008380 A1 WO 03008380A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid derivatives
compounds
derivatives
gpia
Prior art date
Application number
PCT/JP2002/007250
Other languages
French (fr)
Japanese (ja)
Inventor
Masaru Takayanagi
Naoyuki Fukuchi
Masayuki Sugiki
Fumie Futaki
Shunji Takehana
Yuki Kajigaya
Yayoi Takamatsu
Munetaka Tokumasu
Kaoru Yoshida
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Publication of WO2003008380A1 publication Critical patent/WO2003008380A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The compounds represented by the following formulae, which have α2β1 integrin inhibitory activity (inhibition of bonding between GPIa/IIa and collagen), or analogues thereof; and a remedial or preventive agent for various diseases which contains any of the compounds and derivatives.
PCT/JP2002/007250 2001-07-18 2002-07-17 Carboxylic acid derivatives WO2003008380A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-218507 2001-07-18
JP2001218507 2001-07-18
JP2001-351077 2001-11-16
JP2001351077A JP2005022976A (en) 2001-07-18 2001-11-16 Carboxylic acid derivative

Publications (1)

Publication Number Publication Date
WO2003008380A1 true WO2003008380A1 (en) 2003-01-30

Family

ID=26618950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007250 WO2003008380A1 (en) 2001-07-18 2002-07-17 Carboxylic acid derivatives

Country Status (2)

Country Link
JP (1) JP2005022976A (en)
WO (1) WO2003008380A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034035A1 (en) * 2005-09-16 2007-03-29 Biotie Therapies Corporation Sulphonamide derivatives
JP2007536355A (en) * 2004-05-07 2007-12-13 ラボラトワール フルニエ エス・アー LXR receptor modulator
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
US7910609B2 (en) 2005-06-07 2011-03-22 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 with modified urea moiety
CN102234313A (en) * 2011-08-16 2011-11-09 青岛康地恩药业股份有限公司 Method for synthesizing pidotimod
WO2012038942A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US10131658B2 (en) 2013-09-30 2018-11-20 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283545A (en) * 1976-01-01 1977-07-12 Mitsubishi Chem Ind Ltd Tri-and tetrapeptides and their derivatives
JPS62126197A (en) * 1985-11-26 1987-06-08 Nitto Boseki Co Ltd Novel compound for measuring plasma kallikrein
JPH01117900A (en) * 1987-10-30 1989-05-10 Nitto Boseki Co Ltd Tripeptides and antiplasmine agent containing same
JPH0242047A (en) * 1988-05-27 1990-02-13 Pfizer Inc Cycloalkyl substituted glutaramide diuretic agent
JPH02275886A (en) * 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd Cephalosporin compound and its production
JPH05500954A (en) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Antithrombotic peptides and pseudopeptides
JPH07501788A (en) * 1991-08-09 1995-02-23 ユニロイヤル　ケミカル　カンパニー　インコーポレイテッド Benzene sulfonamide derivatives as herbicides
JPH08505860A (en) * 1993-01-23 1996-06-25 カセラ・アクチェンゲゼルシャフト Substituted amino compound, method for producing the same and method of using the same as an inhibitor of platelet aggregation
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006436A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999043709A2 (en) * 1998-02-27 1999-09-02 The Regents Of The University Of California Melanocortin receptor antagonists and modulations of melanocortin receptor activity
WO2000043415A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
WO2001054690A1 (en) * 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283545A (en) * 1976-01-01 1977-07-12 Mitsubishi Chem Ind Ltd Tri-and tetrapeptides and their derivatives
JPS62126197A (en) * 1985-11-26 1987-06-08 Nitto Boseki Co Ltd Novel compound for measuring plasma kallikrein
JPH01117900A (en) * 1987-10-30 1989-05-10 Nitto Boseki Co Ltd Tripeptides and antiplasmine agent containing same
JPH0242047A (en) * 1988-05-27 1990-02-13 Pfizer Inc Cycloalkyl substituted glutaramide diuretic agent
JPH02275886A (en) * 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd Cephalosporin compound and its production
JPH05500954A (en) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Antithrombotic peptides and pseudopeptides
JPH07501788A (en) * 1991-08-09 1995-02-23 ユニロイヤル　ケミカル　カンパニー　インコーポレイテッド Benzene sulfonamide derivatives as herbicides
JPH08505860A (en) * 1993-01-23 1996-06-25 カセラ・アクチェンゲゼルシャフト Substituted amino compound, method for producing the same and method of using the same as an inhibitor of platelet aggregation
WO1999006432A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999006436A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
WO1999043709A2 (en) * 1998-02-27 1999-09-02 The Regents Of The University Of California Melanocortin receptor antagonists and modulations of melanocortin receptor activity
WO2000043415A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
WO2001054690A1 (en) * 2000-01-28 2001-08-02 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAERTNER H. ET AL.: "Peptide synthesis catalyzed by modified .alpha.-chymotrypsin in low-water organic media", J. ORG. CHEM., vol. 56, no. 9, 1991, pages 3149 - 3153, XP001009792 *
HAGIWARA DAIJIRO ET AL.: "Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N.alpha.-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists", J. MED. CHEM., vol. 36, no. 16, 1993, pages 2266 - 2278, XP002006315 *
HELLIO FLORENCE, GUEGUEN PAUL, MORGAT JEAN LOUIS: "Peptide enzymic microsynthesis, using carboxypeptidase Y as the catalyst: application to stepwise synthesis of Leu-enkephalin", BIOCHIMIE, vol. 70, no. 6, 1988, pages 791 - 802, XP002956674 *
OKA TATSUSHI, MORIHARA KAZUYUKI: "Trypsin as a catalyst for peptide synthesis", J. BIOCHEM., vol. 82, no. 4, 1977, TOKYO, pages 1055 - 1062, XP001011246 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
JP2007536355A (en) * 2004-05-07 2007-12-13 ラボラトワール フルニエ エス・アー LXR receptor modulator
JP4892475B2 (en) * 2004-05-07 2012-03-07 ラボラトワール フルニエ エス・アー LXR receptor modulator
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US7910609B2 (en) 2005-06-07 2011-03-22 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 with modified urea moiety
US8258159B2 (en) 2005-06-07 2012-09-04 The Trustees Of The University Of Pennsylvania Inhibitors of the α2β1/GPIa-IIa integrin
WO2007034035A1 (en) * 2005-09-16 2007-03-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2012038942A1 (en) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
CN102234313A (en) * 2011-08-16 2011-11-09 青岛康地恩药业股份有限公司 Method for synthesizing pidotimod
US10131658B2 (en) 2013-09-30 2018-11-20 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
JP2005022976A (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2003008380A1 (en) Carboxylic acid derivatives
EP1889842A4 (en) Heterocyclic compound
WO2005000332A3 (en) Therapeutic agent for soft tissue sarcoma
MXPA04004674A (en) Cannabinoid receptor ligands.
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
EP1704856A4 (en) Hsp90 family protein inhibitor
NO20032233L (en) Synergistic compounds which include a renin inhibitor for cardiovascular diseases
AU2002363746A1 (en) Inventory early warning agent with correction by error correlation calculation
AU2002310156A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
EP1541551A8 (en) 2-cyano-4-fluoropyrrolidine derivative or its salt
RS52625B (en) Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2003000220A3 (en) Use of 1,2-decandiol for combating germs causing body odour
CL2008003324A1 (en) Liquid immediate release pharmaceutical formulation comprising an acid addition salt of a substituted azetidine derivative compound and a pharmaceutically acceptable diluent or carrier useful for the treatment or prevention of thrombosis.
WO2002080899A1 (en) Remedial agent for digestive disease
WO2003047520A3 (en) SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2002076918A8 (en) NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
CA2468039A1 (en) Novel peptide having angiotensin converting enzyme inhibitory effect
WO2002034201A3 (en) Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
WO2003035650A1 (en) Entry inhibitor
NO20043211L (en) Imidazo [1,2-a] pyridine derivative
WO2005005461A3 (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
WO2002071218A3 (en) Method of and system for withdrawing budget from a blocking task

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP